Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 152

Results For "ET"

10694 News Found

Granules India’s Gagillapur facility completes USFDA inspection
Drug Approval | January 16, 2023

Granules India’s Gagillapur facility completes USFDA inspection

The company will respond to these observations within the stipulated time period.


Global (68M) cardiomyopathies market set to reach $9.63 bn by 2031: GlobalData
News | January 14, 2023

Global (68M) cardiomyopathies market set to reach $9.63 bn by 2031: GlobalData

The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%


Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets
Drug Approval | January 13, 2023

Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets

Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults


Merck completes tender offer to acquire Imago BioSciences
News | January 12, 2023

Merck completes tender offer to acquire Imago BioSciences

Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago


Sun Pharma launches Palbociclib, a novel targeted therapy for advanced breast cancer
News | January 12, 2023

Sun Pharma launches Palbociclib, a novel targeted therapy for advanced breast cancer

Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies


Zydus receives final approval from the USFDA for Febuxostat Tablets
Drug Approval | January 10, 2023

Zydus receives final approval from the USFDA for Febuxostat Tablets

Febuxostat tablets had annual sales of USD 32 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).


Sirio Pharma successfully completes acquisition of Best Formulations
News | January 10, 2023

Sirio Pharma successfully completes acquisition of Best Formulations

With more than 35 years of experience, Best Formulations is the largest manufacturer of plant-based softgels in the United States, with newly expanded capabilities for nutritional gummies and personal care


Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).


Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022